Breast Cancer Resistance Protein (Bcrp) Substrates has 3 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alpelisib, Capmatinib, Vanzacaftor, Tezacaftor, And Deutivacaftor. Patients taking Breast Cancer Resistance Protein (Bcrp) Substrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 3
- Major
- 1
- Moderate
- 2
Major (1)
- Breast Cancer Resistance Protein (Bcrp) Substrates + Alpelisib— BCRP inhibitors may increase alpelisib concentration, which may increase the risk of toxicities. Avoid use or closely mo…
Moderate (2)
- Breast Cancer Resistance Protein (Bcrp) Substrates + Capmatinib— Coadministration increased BCRP substrate exposure, which may increase adverse reactions. Decrease substrate dosage if c…
- Breast Cancer Resistance Protein (Bcrp) Substrates + Vanzacaftor, Tezacaftor, And Deutivacaftor— Monitor more frequently for adverse reactions. Vanzacaftor and deutivacaftor are BCRP inhibitors in vitro that may incre…